February 19, 2014

MicroBiome’s diabetes drug shows promise

BROOMFIELD – A research drug that can help people with Type 2 diabetes control their blood glucose levels did well in a recent clinical trial, according to MicroBiome Therapeutics LLC, the company that’s developing the drug.

Broomfield-based MicroBiome reported that the research drug called NM504 kept blood glucose levels within normal limits for patients involved in a four-week clinical trial. The research drug works by shifting a diabetic or pre-diabetic person’s gut bacteria to make it behave more like a healthy person’s gut bacteria, said Barbara Lindheim, a company spokeswoman.

Studies have shown that Type 2 diabetics typically have microbial imbalances…

Categories:
Sign up for BizWest Daily Alerts
Closing in 8 seconds...